OHSU Emergency Department reports fewer meth-related visits following 2006 'anti-meth' legislation

June 05, 2010

PORTLAND, Ore. -- The number of methamphetamine-related emergency room visits decreased significantly in the year following the implementation of Oregon's law prohibiting the sale of over-the-counter decongestant containing pseudoephedrine, according to Oregon Health & Science Emergency Department physician-researchers.

Their findings will be presented Saturday, June 5, at the annual meeting of the Society of Academic Emergency Medicine in Phoenix, Ariz.

"This is one of the first studies to suggest that limitation of supply of an illicit substance may be effective at decreasing its use as well as its associated medical problems," said Rob Hendrickson, M.D., principal investigator, medical toxicologist and an associate professor of emergency medicine in the OHSU School of Medicine. "Our research suggests that the state legislation limiting the supply of methamphetamine was associated with a decrease in methamphetamine use and, in particular, a decrease in medical problems related to methamphetamine."

Methamphetamine is an illegal drug of abuse typically produced through the chemical conversion of over-the-counter pseudoephedrine. In July 2006 Oregon became the first state to make over-the-counter medicines containing ephedrine, pseudoephedrine and phenylpropanolamine -- key ingredients used in the illegal manufacture of meth -- prescription-only drugs.

Following the law's implementation, Hendrickson and colleagues in the OHSU Emergency Department (ED) sought to determine whether the new legislation was an effective deterrent of methamphetamine use or methamphetamine-related disorders.

To conduct their research, the research team queried OHSU ED physicians to determine whether each individual patient visit to the ED was methamphetamine-related. The ED physicians were required to enter a response in the patient's electronic medical record prior to discharge. A database was kept and 38,417 patients were recorded. Of those patient encounters, 721 were deemed meth-related.

Following the one-year study, Feb. 5, 2006, to Feb. 5, 2007, the researchers found a 35 percent decrease in visits to the ED that were related to methamphetamine and a 29 percent decrease in patients who admitted to methamphetamine use. They also report that in the months prior to the law's enactment, they had an average of 18 methamphetamine-related Emergency Department visits per week in the OHSU ED. Post-legislation, that number fell to an average 11.3 per week.

"We are hoping to further explore if the decreases that we see in methamphetamine-related visits continue in the future and if further limitations of supply or other interventions affect ED visits," Hendrickson said.
Co-investigators on the study are Robert Cloutier, M.D., assistant professor of emergency medicine, and K. John McConnell, Ph.D., associate professor of emergency medicine, both of the OHSU School of Medicine.

About Oregon Health & Science University

Oregon Health & Science University is the state's only health and research university and Oregon's only academic health center. OHSU is Portland's largest employer and the fourth largest in Oregon (excluding government). OHSU's size contributes to its ability to provide many services and community support activities not found anywhere else in the state. It serves patients from every corner of the state, and is a conduit for learning for more than 3,400 students and trainees. OHSU is the source of more than 200 community outreach programs that bring health and education services to every county in the state

Oregon Health & Science University

Related Methamphetamine Articles from Brightsurf:

Study explores link between methamphetamine use and risky sexual behavior
Recreational use of the illicit drug methamphetamine has long been associated with increases in overall impatient and risky behavior.

Impact of methamphetamine use depends on your genes
The research, published in Molecular Psychiatry found that variations in the gene known as BDNF strongly determine the effects of methamphetamine in the brain.

Co-addiction of meth and opioids hinders treatment
A study published in the Journal of Substance Abuse Treatment found that methamphetamine use was associated with more than twice the risk for dropping out of treatment for opioid-use disorder.

Mapping international drug use through the world's largest wastewater study
A seven-year project monitoring illicit drug use in 37 countries via wastewater samples shows that cocaine use was skyrocketing in Europe in 2017 and Australia had a serious problem with methamphetamine.

A rat's brain, on and off methamphetamine
Drug addiction is a vicious cycle of reward and withdrawal.

The science Of Breaking Bad: Would you know if meth was cooked inside your house?
Researchers analysed the contamination levels in household items from a home suspected to have previously been used for cooking methamphetamine, to determine whether surface wipe samples can adequately establish contamination and define the health risks.

Spending on illicit drugs in US nears $150 billion annually
Spending on cannabis, cocaine, heroin and methamphetamine fluctuated between $120 billion and $145 billion each year from 2006 to 2016, rivaling what Americans spend each year on alcohol, according to a new study.

Psychostimulants play a major role in fatal strokes among young adults
An estimated 76 million people use psychostimulants, which include illicit drugs such as methamphetamine, cocaine, and 3,4-methylenedioxymethamphetamine, as well as prescription stimulants.

New study examines the way estrogen affects methamphetamine addiction
MUSC researchers look at how methamphetamine affects female rats in a new study published January 10 eNeuro.

New study suggests ovarian hormone may make drug withdrawal symptoms worse for women
Researchers found that a form of the estrogen hormone can contribute to drug relapse in females by worsening withdrawal symptoms.

Read More: Methamphetamine News and Methamphetamine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.